Target Intestinal Microbiota to Alleviate Disease Progression in Amyotrophic Lateral Sclerosis

Clinical Therapeutics

Volumn 39, Issue 2, 2017, Pages 322-336

  Zhang, Yong guo ^a   Wu, Shaoping ^b   Yi, Jianxun ^c   Xia, Yinglin ^a   Jin, Dapeng ^a   Zhou, Jingsong ^c   Sun, Jun ^a  

^a UNIVERSITY OF ILLINOIS   (United States)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

Author keywords

ALS; butyrate; dysbiosis; intestinal permeability; microbiome; tight junctions

Indexed keywords

BUTYRIC ACID; COPPER ZINC SUPEROXIDE DISMUTASE; RNA 16S; SOD1 G93A PROTEIN; SUPEROXIDE DISMUTASE;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL COUNT; CONTROLLED STUDY; DISEASE COURSE; DYSBIOSIS; HOMEOSTASIS; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; INTESTINE EPITHELIUM CELL; INTESTINE FLORA; LIFESPAN; MICROBIAL COMMUNITY; MOUSE; NONHUMAN; PANETH CELL; PATHOPHYSIOLOGY; REAL TIME POLYMERASE CHAIN REACTION; TREATMENT DURATION; WESTERN BLOTTING; ANIMAL; DISEASE MODEL; METABOLISM; MOTONEURON; PATHOLOGY; QUALITY OF LIFE; TRANSGENIC MOUSE;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; GASTROINTESTINAL MICROBIOME; HUMANS; MICE; MICE, TRANSGENIC; MOTOR NEURONS; QUALITY OF LIFE; SUPEROXIDE DISMUTASE;

EID: 85010223761     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2016.12.014     Document Type: Article

References (48)

1. 1 Alonso, A., Logroscino, G., Jick, S.S., Hernan, M.A., Incidence and lifetime risk of motor neuron disease in the United Kingdom: a population-based study. Eur J Neurol 16 (2009), 745–751.
2. 2 Joyce, P.I., Fratta, P., Fisher, E.M., Acevedo-Arozena, A., SOD1 and TDP-43 animal models of amyotrophic lateral sclerosis: recent advances in understanding disease toward the development of clinical treatments. Mamm Genome 22 (2011), 420–448.
3. 3 Forsyth, C.B., Shannon, K.M., Kordower, J.H., et al. Increased intestinal permeability correlates with sigmoid mucosa alpha-synuclein staining and endotoxin exposure markers in early Parkinson׳s disease. PloS One, 6, 2011, e28032.
4. 4 Hsiao, E.Y., McBride, S.W., Hsien, S., et al. Microbiota modulate behavioral and physiological abnormalities associated with neurodevelopmental disorders. Cell 155 (2013), 1451–1463.
5. 5 Gurney, M.E., Pu, H., Chiu, A.Y., et al. Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. Science 264 (1994), 1772–1775.
6. 6 Wu, S., Yi, J., Zhang, Y.G., et al. Leaky intestine and impaired microbiome in an amyotrophic lateral sclerosis mouse model. Physiol Rep, 3, 2015, e12356.
7. 7 Deng, H.X., Shi, Y., Furukawa, Y., et al. Conversion to the amyotrophic lateral sclerosis phenotype is associated with intermolecular linked insoluble aggregates of SOD1 in mitochondria. Proc Nat Acad Sci U S A 103 (2006), 7142–7147.
8. 8 Ivanova, M.I., Sievers, S.A., Guenther, E.L., et al. Aggregation-triggering segments of SOD1 fibril formation support a common pathway for familial and sporadic ALS. Proc Nat Acad Sci U S A 111 (2014), 197–201.
9. 9 Kim, J., Lee, H., Lee, J.H., et al. Dimerization, oligomerization, and aggregation of human Amyotrophic lateral sclerosis Cu/Zn-superoxide dismutase 1 mutant forms in live cells. J Biol Chem, 2014.
10. 10 Wu, S., Zhang, Y.G., Lu, R., et al. Intestinal epithelial vitamin D receptor deletion leads to defective autophagy in colitis. Gut, 2014.
11. 11 Zhang, Y.G., Wu, S., Xia, Y., Sun, J., Salmonella infection upregulates the leaky protein claudin-2 in intestinal epithelial cells. PLoS One, 8, 2013, e58606.
12. 12 Liao, A.P., Petrof, E.O., Kuppireddi, S., et al. Salmonella type III effector AvrA stabilizes cell tight junctions to inhibit inflammation in intestinal epithelial cells. PLoS One, 3, 2008, e2369.
13. 13 Cadwell, K., Liu, J.Y., Brown, S.L., et al. A key role for autophagy and the autophagy gene Atg16l1 in mouse and human intestinal Paneth cells. Nature 456 (2008), 259–263.
14. 14 Louis, P., Flint, H.J., Development of a semiquantitative degenerate real-time pcr-based assay for estimation of numbers of butyryl-coenzyme A (CoA) CoA transferase genes in complex bacterial samples. Appl Environ Microbiol 73 (2007), 2009–2012.
15. 15 Edgar, R.C., Search and clustering orders of magnitude faster than BLAST. Bioinformatics 26 (2010), 2460–2461.
16. 16 Edgar, R.C., Haas, B.J., Clemente, J.C., et al. UCHIME improves sensitivity and speed of chimera detection. Bioinformatics 27 (2011), 2194–2200.
17. 17 McHardy, I.H., Li, X., Tong, M., et al. HIV Infection is associated with compositional and functional shifts in the rectal mucosal microbiota. Microbiome, 1, 2013, 26.
18. 18 Caporaso, J.G., Kuczynski, J., Stombaugh, J., et al. QIIME allows analysis of high-throughput community sequencing data. Nat Methods 7 (2010), 335–336.
19. 19 Louis, P., Flint, H.J., Diversity, metabolism and microbial ecology of butyrate-producing bacteria from the human large intestine. FEMS Microbiol Lett 294 (2009), 1–8.
20. 20 Duncan, S.H., Barcenilla, A., Stewart, C.S., et al. Acetate utilization and butyryl coenzyme A (CoA):acetate-CoA transferase in butyrate-producing bacteria from the human large intestine. Appl Environ Microbiol 68 (2002), 5186–5190.
21. 21 Ley, R.E., Peterson, D.A., Gordon, J.I., Ecological and evolutionary forces shaping microbial diversity in the human intestine. Cell 124 (2006), 837–848.
22. 22 Ley, R.E., Turnbaugh, P.J., Klein, S., Gordon, J.I., Microbial ecology: human gut microbes associated with obesity. Nature 444 (2006), 1022–1023.
23. 23 Henig R.M. Fat factors. New York Times Magazine 2008-09-28.
24. 24 Ley, R.E., Backhed, F., Turnbaugh, P., et al. Obesity alters gut microbial ecology. Proc Nat Acad Sci U S A 102 (2005), 11070–11075.
25. 25 Vital, M., Howe, A.C., Tiedje, J.M., Revealing the bacterial butyrate synthesis pathways by analyzing (meta)genomic data. mBio, 5, 2014, e00889.
26. 26 Barcenilla, A., Pryde, S.E., Martin, J.C., et al. Phylogenetic relationships of butyrate-producing bacteria from the human gut. Appl Environ Microbiol 66 (2000), 1654–1661.
27. 27 Lee, H.R., Jun, H.K., Choi, B.K., Tannerella forsythia BspA increases the risk factors for atherosclerosis in ApoE(-/-) mice. Oral Dis 20 (2014), 803–808.
28. 28 Davie, J.R., Inhibition of histone deacetylase activity by butyrate. J Nutr 133 (2003), 2485S–2493S.
29. 29 Donohoe, D.R., Garge, N., Zhang, X., et al. The microbiome and butyrate regulate energy metabolism and autophagy in the mammalian colon. Cell Metab 13 (2011), 517–526.
30. 30 Hamer, H.M., Jonkers, D.M., Bast, A., et al. Butyrate modulates oxidative stress in the colonic mucosa of healthy humans. Clin Nutr 28 (2009), 88–93.
31. 31 Hamer, H.M., Jonkers, D., Venema, K., et al. Review article: the role of butyrate on colonic function. Aliment Pharmacol Ther 27 (2008), 104–119.
32. 32 Samuel, B.S., Shaito, A., Motoike, T., et al. Effects of the gut microbiota on host adiposity are modulated by the short-chain fatty-acid binding G protein-coupled receptor, Gpr41. Proc Nat Acad Sci U S A 105 (2008), 16767–16772.
33. 33 Wen, L., Ley, R.E., Volchkov, P.Y., et al. Innate immunity and intestinal microbiota in the development of Type 1 diabetes. Nature 455 (2008), 1109–1113.
34. 34 Arumugam, M., Raes, J., Pelletier, E., et al. Enterotypes of the human gut microbiome. Nature 473 (2011), 174–180.
35. 35 Lathrop, S.K., Bloom, S.M., Rao, S.M., et al. Peripheral education of the immune system by colonic commensal microbiota. Nature 478 (2011), 250–254.
36. 36 Furusawa, Y., Obata, Y., Fukuda, S., et al. Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. Nature 504 (2013), 446–450.
37. 37 Le Poul, E., Loison, C., Struyf, S., et al. Functional characterization of human receptors for short chain fatty acids and their role in polymorphonuclear cell activation. J Biol Chem 278 (2003), 25481–25489.
38. 38 Ryu, H., Smith, K., Camelo, S.I., et al. Sodium phenylbutyrate prolongs survival and regulates expression of anti-apoptotic genes in transgenic amyotrophic lateral sclerosis mice. J Neurochem 93 (2005), 1087–1098.
39. 39 Cudkowicz, M.E., Andres, P.L., Macdonald, S.A., et al. Phase 2 study of sodium phenylbutyrate in ALS. Amyotroph Lateral Scler 10 (2009), 99–106.
40. 40 Redler, R.L., Dokholyan, N.V., The complex molecular biology of amyotrophic lateral sclerosis (ALS). Progr Mol Biol Transl Sci 107 (2012), 215–262.
41. 41 Gao, Z., Yin, J., Zhang, J., et al. Butyrate improves insulin sensitivity and increases energy expenditure in mice. Diabetes 58 (2009), 1509–1517.
42. 42 Kolar, S., Barhoumi, R., Jones, C.K., et al. Interactive effects of fatty acid and butyrate-induced mitochondrial Ca(2)(+) loading and apoptosis in colonocytes. Cancer 117 (2011), 5294–5303.
43. 43 Tang, Y., Chen, Y., Jiang, H., Nie, D., The role of short-chain fatty acids in orchestrating two types of programmed cell death in colon cancer. Autophagy 7 (2011), 235–237.
44. 44 Tang, Y., Chen, Y., Jiang, H., Nie, D., Short-chain fatty acids induced autophagy serves as an adaptive strategy for retarding mitochondria-mediated apoptotic cell death. Cell Death Differ 18 (2011), 602–618.
45. 45 Iannitti, T., Beniamino Palmieri, B., Clinical and experimental applications of sodium phenylbutyrate. Drug R D 11 (2011), 227–249.
46. 46 Zhang, R., Miller, R.G., Gascon, R., et al. Circulating endotoxin and systemic immune activation in sporadic amyotrophic lateral sclerosis (sALS). J Neuroimmunol 206 (2009), 121–124.
47. 47 Forshew, D.A., Bromberg, M.B., A survey of clinicians׳ practice in the symptomatic treatment of ALS. Amyotroph Lateral Scler Other Motor Neuron Disord 4 (2003), 258–263.
48. 48 Sun, J., Zhou, J., Does the gut drive amyotrophic lateral sclerosis progress?. Neurodegener Dis Manag 5 (2015), 375–378.